News + Filings Transactions Holdings
All 13F 13D/G Other
|
Versant Venture Capital III, L.P.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/10/2016 |
4
| Versant Ventures III, LLC (10% Owner) has filed a Form 4 on Flexion Therapeutics Inc
Txns:
| Bought 710,091 shares
@ $14, valued at
$9.9M
Bought 4,194 shares
@ $14, valued at
$58.7k
|
|
05/24/2016 |
4
| ATWOOD BRIAN G (10% Owner) has filed a Form 4 on PHASERX, INC.
Txns:
| Sold 435 shares
@ $0.01, valued at
$4.4 Sold 1,080 shares
@ $0.01, valued at
$10.8 Bought 3,523 shares
@ $5, valued at
$17.6k
Sold 73,615 shares
@ $0.01, valued at
$736.2 Sold 182,914 shares
@ $0.01, valued at
$1.8k
Bought 596,477 shares
@ $5, valued at
$3M
|
|
06/15/2015 |
4
| Versant Venture Capital III, L.P. (10% Owner) has filed a Form 4 on OCULAR THERAPEUTIX, INC
Txns:
| Sold 318,122 shares
@ $22, valued at
$7M
Sold 1,878 shares
@ $22, valued at
$41.3k
|
|
06/11/2015 |
4
| Versant Venture Capital III, L.P. (10% Owner) has filed a Form 4 on OCULAR THERAPEUTIX, INC
Txns:
| Sold 424,494 shares
@ $22, valued at
$9.3M
Sold 2,506 shares
@ $22, valued at
$55.1k
|
|
05/12/2015 |
4
| Versant Ventures III, LLC (10% Owner) has filed a Form 4 on OPGEN INC
Txns:
| Bought 410,906 shares
@ $6, valued at
$2.5M
Converted 1,153,229 shares
@ $0 Converted 402,348 shares
@ $0 Converted 500,565 shares
@ $0 Bought 2,426 shares
@ $6, valued at
$14.6k
Converted 6,810 shares
@ $0 Converted 2,377 shares
@ $0 Converted 2,957 shares
@ $0 Converted 1,153,229 options to buy
@ $0 Converted 6,810 options to buy
@ $0 Converted 402,348 options to buy
@ $0 |
|
09/12/2014 |
4
| Versant Venture Capital III, L.P. (10% Owner) has filed a Form 4 on Flexion Therapeutics Inc
Txns:
| Exercised (in-or-at-the-money) 2,250 options to buy
@ $17.61, valued at
$39.6k
|
|
09/12/2014 |
4
| Versant Venture Capital III, L.P. (10% Owner) has filed a Form 4 on Flexion Therapeutics Inc
Txns:
| Exercised (in-or-at-the-money) 2,250 options to buy
@ $17.61, valued at
$39.6k
|
|
07/31/2014 |
4
| Versant Venture Capital III, L.P. (10% Owner) has filed a Form 4 on Immune Design Corp.
Txns:
| Converted 733,941 shares
@ $0 Converted 531,840 shares
@ $0 Converted 611,620 shares
@ $0 Converted 305,810 shares
@ $0 Sold 208,334 shares
@ $12, valued at
$2.5M
Bought 233,333 shares
@ $12, valued at
$2.8M
Converted 733,941 preferred shares
@ $0 Converted 531,840 preferred shares
@ $0 Converted 611,620 preferred shares
@ $0 Exercised (in-or-at-the-money) 305,810 options to buy
@ $8.175, valued at
$2.5M
Exercised (in-or-at-the-money) 305,810 preferred shares
@ $0 |
|
07/31/2014 |
4
| Versant Venture Capital III, L.P. (10% Owner) has filed a Form 4 on OCULAR THERAPEUTIX, INC
Txns:
| Converted 2,944,993 shares
@ $0 Converted 17,391 shares
@ $0 Converted 198,826 preferred shares
@ $0 Converted 1,174 preferred shares
@ $0 Converted 1,619,102 preferred shares
@ $0 Converted 9,563 preferred shares
@ $0 Converted 2,433,816 preferred shares
@ $0 Converted 14,372 preferred shares
@ $0 Converted 3,523,039 preferred shares
@ $0 Converted 20,804 preferred shares
@ $0 |
|
02/20/2014 |
4
| Versant Venture Capital III, L.P. (10% Owner) has filed a Form 4 on Flexion Therapeutics Inc
Txns:
| Converted 2,036,697 shares
@ $0 Converted 12,029 shares
@ $0 Converted 356,703 shares
@ $0 Converted 385,629 shares
@ $0 Converted 2,277 shares
@ $0 Bought 305,886 shares
@ $13, valued at
$4M
Bought 1,806 shares
@ $13, valued at
$23.5k
Converted 16,558,351 preferred shares
@ $0 Converted 97,797 preferred shares
@ $0 Converted 2,900,000 preferred shares
@ $0 Converted 3,135,165 preferred shares
@ $0 |
|
11/04/2013 |
4
| Versant Ventures III, LLC (10% Owner) has filed a Form 4 on VERACYTE, INC.
Txns:
| Converted 3,594,989 shares
@ $0 Converted 21,232 shares
@ $0 Converted 7,190,864 convertible preferred
@ $0 Converted 42,469 convertible preferred
@ $0 Converted 3,992,420 convertible preferred
@ $0 Converted 23,580 convertible preferred
@ $0 Converted 3,196,673 convertible preferred
@ $0 Converted 18,880 convertible preferred
@ $0 |
|
08/10/2010 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|
|